Söndag 10 November | 10:21:56 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

Tid*
2024-11-07 - Kvartalsrapport 2024-Q3
2024-08-15 - Kvartalsrapport 2024-Q2
2024-05-16 - Kvartalsrapport 2024-Q1
2024-03-21 - X-dag ordinarie utdelning ZEAL 0.00 DKK
2024-03-20 - Årsstämma
2024-02-27 - Bokslutskommuniké 2023
2023-11-09 - Kvartalsrapport 2023-Q3
2023-08-17 - Kvartalsrapport 2023-Q2
2023-05-11 - Kvartalsrapport 2023-Q1
2023-03-30 - X-dag ordinarie utdelning ZEAL 0.00 DKK
2023-03-29 - Årsstämma
2023-03-02 - Bokslutskommuniké 2022
2022-11-10 - Kvartalsrapport 2022-Q3
2022-08-11 - Kvartalsrapport 2022-Q2
2022-05-12 - Kvartalsrapport 2022-Q1
2022-05-09 - X-dag ordinarie utdelning ZEAL 0.00 DKK
2022-04-06 - Årsstämma
2022-03-10 - Bokslutskommuniké 2021
2021-11-11 - Kvartalsrapport 2021-Q3
2021-08-12 - Kvartalsrapport 2021-Q2
2021-05-12 - Kvartalsrapport 2021-Q1
2021-04-16 - X-dag ordinarie utdelning ZEAL 0.00 DKK
2021-04-15 - Årsstämma
2021-03-11 - Bokslutskommuniké 2020
2020-11-12 - Kvartalsrapport 2020-Q3
2020-08-13 - Kvartalsrapport 2020-Q2
2020-05-14 - Kvartalsrapport 2020-Q1
2020-04-03 - X-dag ordinarie utdelning ZEAL 0.00 DKK
2020-04-02 - Årsstämma
2020-03-12 - Bokslutskommuniké 2019
2019-11-14 - Kvartalsrapport 2019-Q3
2019-08-15 - Kvartalsrapport 2019-Q2
2019-05-16 - Kvartalsrapport 2019-Q1
2019-04-05 - X-dag ordinarie utdelning ZEAL 0.00 DKK
2019-04-04 - Årsstämma
2019-03-07 - Bokslutskommuniké 2018
2018-11-15 - Kvartalsrapport 2018-Q3
2018-08-16 - Kvartalsrapport 2018-Q2
2018-05-16 - Kvartalsrapport 2018-Q1
2018-04-20 - X-dag ordinarie utdelning ZEAL 0.00 DKK
2018-04-19 - Årsstämma
2018-03-07 - Bokslutskommuniké 2017
2017-11-08 - Kvartalsrapport 2017-Q3
2017-08-24 - Kvartalsrapport 2017-Q2
2017-05-17 - Kvartalsrapport 2017-Q1
2017-04-06 - X-dag ordinarie utdelning ZEAL 0.00 DKK
2017-04-05 - Årsstämma
2017-03-15 - Bokslutskommuniké 2016
2016-11-09 - Kvartalsrapport 2016-Q3
2016-08-25 - Kvartalsrapport 2016-Q2
2016-05-18 - Kvartalsrapport 2016-Q1
2016-04-20 - X-dag ordinarie utdelning ZEAL 0.00 DKK
2016-04-19 - Årsstämma
2016-03-16 - Bokslutskommuniké 2015
2015-11-05 - Kvartalsrapport 2015-Q3
2015-08-28 - Kvartalsrapport 2015-Q2
2015-05-22 - Kvartalsrapport 2015-Q1
2015-04-22 - X-dag ordinarie utdelning ZEAL 0.00 DKK
2015-04-21 - Årsstämma
2015-03-12 - Bokslutskommuniké 2014
2014-11-07 - Kvartalsrapport 2014-Q3
2014-08-21 - Kvartalsrapport 2014-Q2
2014-05-06 - Kapitalmarknadsdag 2014
2014-04-29 - Kvartalsrapport 2014-Q1
2014-04-29 - Årsstämma
2014-03-21 - X-dag ordinarie utdelning ZEAL 0.00 DKK
2014-03-20 - Bokslutskommuniké 2013
2013-11-15 - Kvartalsrapport 2013-Q3
2013-08-29 - Kvartalsrapport 2013-Q2
2013-05-15 - Kvartalsrapport 2013-Q1
2013-04-30 - Årsstämma
2013-04-30 - X-dag ordinarie utdelning ZEAL 0.00 DKK
2013-03-14 - Bokslutskommuniké 2012
2012-11-29 - Kapitalmarknadsdag 2012
2012-04-26 - X-dag ordinarie utdelning ZEAL 0.00 DKK
2012-04-25 - Årsstämma
2011-11-17 - Kvartalsrapport 2011-Q3
2011-10-25 - Kapitalmarknadsdag 2011
2011-08-18 - Kvartalsrapport 2011-Q2
2011-05-12 - Kvartalsrapport 2011-Q1
2011-04-29 - X-dag ordinarie utdelning ZEAL 0.00 DKK
2011-04-28 - Årsstämma

Beskrivning

LandDanmark
ListaLarge Cap Copenhagen
SektorHälsovård
IndustriBioteknik
Zealand Pharma är verksamt inom bioteknik. Särskilt fokus återfinns inom utvecklingen av läkemedel för behandling av diabetes och diverse tarmsjukdomar. Bolaget innehar en varierad produktportfölj med separata varumärken som säljs på global nivå. Störst verksamhet finns inom den nordiska marknaden. Zealand Pharma grundades 1997 och har sitt huvudkontor i Söborg, Danmark.
2021-04-29 12:00:00

Company announcement – No. 23 / 2021

Zealand Pharma launches long-term incentive program for Zealand’s Board of Directors and grants for 2021


Copenhagen, DK and Boston, MA, U.S., April 29, 2021 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, announces the implementation of a new share-based long-term incentive program for Zealand’s Board of Directors in accordance with Zealand's Remuneration Policy as adopted at the annual general meeting held on April 15, 2021. Accordingly, Zealand has granted 40,500 restricted stock units ("RSUs") to the Board of Directors.

To the extent that the Board member holds any additional role as member of Zealand's Audit Committee, Remuneration Committee and/or Scientific Committee, the Board member has received an additional grant of RSUs in accordance with the Remuneration Policy. Such grants are included in the above-mentioned number.

The 2021 RSU grants to the Board of Directors vest on the date of Zealand's annual general meeting 2022. For each member of the Board, there is an upper limit of 8,000 RSUs (with an absolute value cap of DKK 2.4 million) for the grant. Each vested RSU entitles the holder to receive one share in Zealand at no cost, provided the holder's continued membership of the Board (or Board Committee where relevant).

Each member of the Board is subject to a holding requirement to be met within a period of 5 years. The members of the Board of Directors are also subject to a holding requirement to be met within a period of 5 years if they continue to be members of the Board. This is to align interests of the Board and the shareholders. The holding requirement for the members in question amounts to DKK 300,000.

The grant of RSUs for the members of the Board under this program will have an estimated fair market value of DKK 8.3 million, based on each RSU having a fair value of DKK 205. The value of the RSUs is determined as the closing price of the Company's share on Nasdaq Copenhagen A/S the day prior to the grant.

Zealand Pharma A/S

The Board of Directors

# # #

About Zealand Pharma A/S 

Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development, and commercialization of next generation peptide-based medicines that change the lives of people living with metabolic and gastrointestinal diseases. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s robust pipeline of investigational medicines includes three candidates in late stage development, and one candidate being reviewed for regulatory approval in the United States. Zealand markets V-Go®, an all-in-one basal-bolus insulin delivery option for people with diabetes. License collaborations with Boehringer Ingelheim and Alexion Pharmaceuticals create opportunity for more patients to potentially benefit from Zealand-invented peptide therapeutics. Zealand was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S. that includes key locations in New York, Boston, and Marlborough (MA). For more information about Zealand’s business and activities, please visit http://www.zealandpharma.com.

Forward-Looking Statement

The above information contains forward-looking statements that provide Zealand Pharma’s expectations or forecasts of future events. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions, which may cause actual results to differ materially from expectations set forth herein and may cause any or all of such forward-looking statements to be incorrect. If any or all of such forward-looking statements prove to be incorrect, our actual results could differ materially and adversely from those anticipated or implied by such statements. All such forward-looking statements speak only as of the date of this release and are based on information available to Zealand Pharma as of the date of this release.

For further information, please contact:

Zealand Pharma Investor Relations
Claudia Styslinger
Argot Partners
investors@zealandpharma.com

Zealand Pharma Media Relations
David Rosen
Argot Partners
media@zealandpharma.com

Claudia Styslinger